This licensing of splenic cDCs matched the increase of splenic DC numbers seen in Fig. 1c, whereas tumor-resident cDCs remained unchanged (Fig. 1b and Supplementary Fig. 2C), suggesting that cDCs respond differently to m1928z-CD40L CAR T cell treatment depending on their tissue site. The gene discussed is CD40LG; the disease is neoplasm.